The UK Neurology Clinical Trials market is projected to grow from $342.2 Mn in 2022 to $451.4 Mn by 2030, registering a CAGR of 3.52% during the forecast period of 2022 - 2030. The market will be driven by increasing funding and assistance from institutions such as the NIHR as well as greater awareness and understanding of neurological disorders. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Biogen Inc & Cambridge Cognition Holdings PLC.
The UK Neurology Clinical Trials market is projected to grow from $342.2 Mn in 2022 to $451.4 Mn by 2030, registering a CAGR of 3.52% during the forecast period of 2022 - 2030. The NHS delivers high-quality treatment by global standards; the United Kingdom's healthcare system was placed 10th overall in the 2021 Global Index of Health Innovation. Healthcare costs around 18% of a citizen's income tax, or 4.5% of an ordinary citizen's income. In the United Kingdom, 600,000 people have epilepsy, accounting for around one in every 100 persons. Every day, 87 individuals are diagnosed. Currently, Parkinson's Disease affects 145,000 persons in the United Kingdom.
Neurology clinical trials are a significant field of study in the United Kingdom, with several studies now underway. Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, and stroke are among the conditions being examined. The National Institute for Health and Care Research (NIHR) Clinical Research Network (CRN) provides researchers with the practical assistance they need to make clinical trials happen in both the NHS and the broader healthcare and social care setting. The CRN funds research in 30 different speciality therapeutic areas. There are also various neurological research organisations in the UK, such as the UK Dementia Research Institute, Parkinson's UK, and the MS Society. In their particular areas of specialisation, these organisations invest in research as well as provide resources and assistance for clinical trials.
Market Growth Drivers
The UK has a solid clinical trial ecosystem, including a well-developed regulatory framework, a matrix of research centres and hospitals, and an engaged patient population. The significant worldwide burden of neurological illnesses has raised financial support and shareholders’ interest in supporting neurological clinical investigations is on the rise. The National Institute for Health Research (NIHR) funds and supports clinical trials in the UK and collaborates closely with the NHS to ensure that studies are carried out to the highest standards. Furthermore, the UK has a varied and active patient population, which makes it a desirable place for clinical studies. The UK is a thriving centre for neurology clinical trials, and it is expected to make substantial contributions to the progress of the management and understanding of neurological disorders.
According to current data, the UK has lesser neurology consultants than other high-income nations. There have been concerns with regard to the impact on those with neurological problems obtaining timely access to health and care services. There are additionally more factors that may have an influence on the growth of neurology clinical trials in the UK. One such constraint is the increased struggle for financing, as many other areas of study demand funds as well. Also, the regulatory environment for clinical trials can be complicated and time-consuming, which can add to the cost and duration of investigations.
There is also the possibility that Brexit may have an influence on clinical trials in the UK, as the country's withdrawal from the EU will limit its capacity to partner with other nations and access specific funding sources.
Global Key Players
Local Key Players
February 2023, Pfizer announced that Phase 3 data for Zavegepant for the Acute Management of Migraine in Adults was published in The Lancet Neurology.
November 2022, Biogen Inc. and Eisai Co., Ltd. announced the findings of Eisai's large global Phase 3 confirmatory Clarity AD clinical study of lecanemab, an investigational anti-amyloid beta (A) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD) with confirmed amyloid pathology in the brain.
The Medicines and Healthcare products Regulatory Agency is the regulatory authority in the UK in charge of clinical trials (MHRA). The MHRA guarantees that clinical trials are done safely and ethically and that the items being tested fulfil the appropriate quality, safety, and efficacy requirements.
In the United Kingdom, clinical trials are funded by a variety of public and private organisations, including charities (typically focused on a specific disease), the UK government through organizations such as the National Institute for Health Research (NIHR) or the Medical Research Council (MRC), pharmaceutical companies, and international organisations.
1. Report Description of the UK Neurology Clinical Trials Market
1.1 Research Scope and Assumption
1.2 Objective of the study
1.3 Research Methodology
1.4 Reason to buy the report
2. UK Neurology Clinical Trials Market Executive Summary
2.1 UK Neurology Clinical Trials Market –Industry Snapshot & key buying criteria, 2021-2030
2.2 Market Size, Growth Prospects, and Key findings
3. Market Dynamics of UK Neurology Clinical Trials Market
3.1 Market Growth Drivers Analysis
3.2 Market Restrains Analysis
4. UK Neurology Clinical Trials Market Segmentation
4.1 By Phase
4.1.1 Phase I
4.1.2 Phase II
4.1.3 Phase III
4.1.4 Phase IV
4.2 By Study Design Outlook
4.2.2 Parkinson's Disease (PD)
4.2.3 Huntington's Disease
4.2.5 Traumatic Brain Injury (TBI)
4.2.6 Amyotrophic Lateral Sclerosis (ALS)
4.2.7 Muscle regeneration
4.3 By Indication Outlook
4.3.3 Expanded Access
5. UK Neurology Clinical Trials Market Share
5.1 Market Analysis, Insights, and Forecast – By Revenue
6. Competitive Landscape
6.1 Major Top Market Players
7. Key Company Profiles
7.1 Company 1
7.1.2 Financial Performance
7.1.3 Product & Services
7.1.4 Strategic initiatives
7.2 Company 2
7.2.2 Financial Performance
7.2.3 Product & Services
7.2.4 Strategic initiatives
7.3 Company 3
7.3.2 Financial Performance
7.3.3 Product & Services
7.3.4 Strategic initiatives
7.4 Company 4
7.4.2 Financial Performance
7.4.3 Product & Services
7.4.4 Strategic initiatives
7.5 Company 5
7.5.2 Financial Performance
7.5.3 Product & Services
7.5.4 Strategic initiatives
8. Healthcare Policies and Regulatory Landscape
8.1 Healthcare Policies in UK
8.2 Regulatory Framework in UK
8.3 Pricing & Reimbursement Scenario in UK Neurology Clinical Trials Market
9. Factors Driving Future Growth
9.1 New Trends and Development UK Neurology Clinical Trials Market
9.2 Future Opportunities
10. Strategic Recommendations
By Phase (Revenue, USD Billion):
By Study Design Outlook (Revenue, USD Billion):
By Indication Outlook (Revenue, USD Billion):
Insights10 will provide you with the reports within 10 key parameters which are:
Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.
Stage I: Market Data Collection
Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.
Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.
Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:
Stage II: Market Data Analysis and Statistical Model
Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.
Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.
The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.
The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.
Data Triangulation & Validation:
Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.
We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.
Stage III: Interpretation and Presentation
Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)
Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to oﬀer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.
Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
This report addresses